Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study

BACKGROUND: Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Although eribulin is well tolerated in patients with heavily pretreated disease, eribulin-induced liver dysfunction (EILD) can occur, resulting in treatment modific...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Takayuki, Tomomatsu, Jyunichi, Fukada, Ippei, Shibayama, Tomoko, Teruya, Natsuki, Ito, Yoshinori, Iwase, Takuji, Ohno, Shinji, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936231/
https://www.ncbi.nlm.nih.gov/pubmed/27389013
http://dx.doi.org/10.1186/s12885-016-2436-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936231/
https://www.ncbi.nlm.nih.gov/pubmed/27389013
http://dx.doi.org/10.1186/s12885-016-2436-5

Ejemplares similares